Pyrazine

Pyrazine

SCHEMBL4235261

O=C(O)C(O)c1cnccn1.c1cnccn1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
HCAR2 Q8TDS4 2/20 0.45
NAPRT Q6XQN6 2/20 0.45
LMNA P02545 4/20 0.43
TSHR P16473 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
MC4R P32245 1/20 0.39
ADRA1A P35348 1/20 0.39
MC3R P41968 1/20 0.39
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 1/20 0.33
HSP90AA1 P07900 1/20 0.32
GAA P10253 2/20 0.32
THRB P10828 1/20 0.32
VNN1 O95497 1/20 0.32
APP P05067 1/20 0.31
HCAR3 P49019 1/20 0.31
BAZ2B Q9UIF8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11678794 0.79 KDM4E (0.48) KDM4EHCAR2NAPRTLMNATSHR
SCHEMBL25660372 0.76 KDM4E (0.45) KDM4EHCAR2NAPRTLMNATSHR
SCHEMBL6037597 0.76 LMNA (0.51) KDM4EHCAR2NAPRTLMNATSHR
Hydrochloric Acid SCHEMBL28153892 0.74 KDM4E (0.44) KDM4EHCAR2NAPRTLMNATSHR
SCHEMBL10484478 0.74 LMNA (0.50) KDM4EHCAR2NAPRTLMNATSHR
SCHEMBL28114415 0.74 ADORA3 (0.47) KDM4EHCAR2NAPRTLMNATSHR
SCHEMBL4264233 0.73
SCHEMBL7746776 0.73 KDM4E (0.42) KDM4EHCAR2NAPRTLMNATSHR
SCHEMBL8602182 0.73 ADORA3 (0.42) KDM4EHCAR2NAPRTLMNATSHR
SCHEMBL8766788 0.72 KDM4E (0.41) KDM4EHCAR2NAPRTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653056-B2 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation UNIVERZITA KARLOVA V PRAZE, PRIRODOVEDECKA FAKULTA (CZ) 2014-02-18 US disclosed
US-20090325919-A1 METHOD OF PREPARATION OF A SOLUBLE FORMULATION OF WATER-INSOLUBLE PENTACYCLIC AND TETRACYCLIC TERPENOIDS, A SOLUBLE FORMULATION OF A PENTACYCLIC OR TETRACYCLIC TERPENOID AND A PHARMACEUTICAL COMPOSITION CONTAINING THIS SOLUBLE FORMULATION UNIVERZITA KARLOVA V PRAZE PRIRODOVEDECKA FAKULTA (CZ) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325919-A1 METHOD OF PREPARATION OF A SOLUBLE FORMULATION OF WATER-INSOLUBLE PENTACYCLIC AND TETRACYCLIC TERPENOIDS, A SOLUBLE FORMULATION OF A PENTACYCLIC OR TETRACYCLIC TERPENOID AND A PHARMACEUTICAL COMPOSITION CONTAINING THIS SOLUBLE FORMULATION OSTC, DCXR, UGGT1 KDM4E 3806/4885HCAR2 1428/4885NAPRT 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.